Teva Pharmaceuticals and Immunai, an AI-driven company specializing in immune system mapping, have announced a partnership focused on optimizing clinical trials in immunology and immuno-oncology. The collaboration aims to leverage Immunai’s proprietary immune cell atlas, AMICA, and its AI model, the Immunodynamics Engine (IDE), to enhance clinical decision-making within Teva's immunology programs. This partnership seeks to improve patient outcomes by providing deeper insights into treatment mechanisms and patient responses.
Collaboration Focus
The multi-year collaboration will concentrate on several key areas, including elucidating drug mechanisms of action, optimizing dose selection, and conducting comprehensive biomarker analyses. By applying Immunai's AI-driven platform, the partnership aims to gain a more granular understanding of how patients respond to treatments, potentially leading to more effective and personalized therapeutic strategies.
Immunai's Technology
Immunai's AMICA platform is a comprehensive atlas of immune cells, providing a detailed map of the human immune system. The Immunodynamics Engine (IDE) uses AI to analyze this data, offering insights into complex immunological processes. This technology aims to streamline the drug development process by identifying potential biomarkers and predicting patient responses, ultimately reducing the time and cost associated with bringing new therapies to market.
Executive Perspectives
Eran Harary, Senior Vice President of Global Early Clinical Development at Teva, stated, "This collaboration will provide important insights into patient responses and treatment mechanisms in immunology and immuno-oncology, allowing us to optimise our clinical trials and improve outcomes for patients." Noam Solomon, Immunai’s Chief Executive Officer, added, "Through our partnership with Teva, we are eager to utilise our AI-based engine, the IDE, to streamline this process and facilitate the delivery of new therapies to patients."
Potential Expansion
While the initial focus is on immunology and immuno-oncology, the partnership has the potential to expand to cover broader aspects of Teva’s research and development portfolio. This could involve applying Immunai's technology to other therapeutic areas and stages of drug development, further enhancing Teva's capabilities in precision medicine.
AstraZeneca Collaboration
This announcement follows Immunai's recent multi-year collaboration with AstraZeneca, which also focuses on clinical decision-making, including dose selection, mechanisms of action, patient responder versus non-responder analysis, as well as biomarker identification. These partnerships highlight the growing importance of AI and machine learning in optimizing clinical trials and accelerating drug development.
